Pharma mar prescribe IRqA como solucion para la mejora de los procesos de Gestión de Requisitos .

GENENTECH INC (US) Patenta ( WO ) aplicaciones de Nuestra Aplidin y ..... Kahalalide .

MACROCYCLIC DEPSIPEPTIDE ANTIBODY-DRUG CONJUGATES AND METHODS

Inventor: JACKSON DAVID Y (US)
Applicant: GENENTECH INC (US); JACKSON DAVID Y (US)
IPC: A61K47/48; A61K38/15; A61P35/00 (+3)
Publication info:
WO2007100385 A2 - 2007-09-07
WO2007100385 A3 - 2007-11-08
Classification:
- international: A61K47/48; A61K38/15; A61P35/00; A61K47/48; A61K38/15; A61P35/00;
- European:
Application number: WO2006US60276 20061026
Priority number(s): US20050731972P 20051031



Abstract of WO2007100385

The present invention relates to antibody-drug conjugate compounds of Formula I: Ab (L D)p I where one or more macrocyclic depsipeptide drug moieties (D), selected from Aplidin, Didemnin B, Kahalalide F, and analogs and derivatives therefrom, are covalently attached by a linker (L) to an antibody (Ab) which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be useful in methods of diagnosis or treatment of cancer, and other diseases and disorders.

¿ El Agua Potable de Barcelona es Cancerigena ? .